JPWO2020102779A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020102779A5 JPWO2020102779A5 JP2021526660A JP2021526660A JPWO2020102779A5 JP WO2020102779 A5 JPWO2020102779 A5 JP WO2020102779A5 JP 2021526660 A JP2021526660 A JP 2021526660A JP 2021526660 A JP2021526660 A JP 2021526660A JP WO2020102779 A5 JPWO2020102779 A5 JP WO2020102779A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- cell
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862768128P | 2018-11-16 | 2018-11-16 | |
| US62/768,128 | 2018-11-16 | ||
| PCT/US2019/061887 WO2020102779A1 (en) | 2018-11-16 | 2019-11-15 | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022513053A JP2022513053A (ja) | 2022-02-07 |
| JPWO2020102779A5 true JPWO2020102779A5 (https=) | 2022-11-08 |
| JP2022513053A5 JP2022513053A5 (https=) | 2022-11-08 |
| JP7682789B2 JP7682789B2 (ja) | 2025-05-26 |
Family
ID=70731685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526660A Active JP7682789B2 (ja) | 2018-11-16 | 2019-11-15 | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12252538B2 (https=) |
| EP (1) | EP3880712A4 (https=) |
| JP (1) | JP7682789B2 (https=) |
| CN (1) | CN113330034A (https=) |
| WO (1) | WO2020102779A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022081888A1 (en) * | 2020-10-15 | 2022-04-21 | The Regents Of The University Of California | Anti-cancer inhibitory antibodies |
| MX2023008895A (es) | 2021-02-09 | 2023-08-09 | Medilink Therapeutics Suzhou Co Ltd | Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo. |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| CN113527493B (zh) * | 2021-07-20 | 2023-10-27 | 广州爱思迈生物医药科技有限公司 | 一种b7-h3抗体及其应用 |
| CN114380910B (zh) * | 2022-01-07 | 2023-04-28 | 苏州旭光科星抗体生物科技有限公司 | 靶向人b7-h3分子的人源化单克隆抗体及其应用 |
| CN118647408A (zh) | 2022-02-16 | 2024-09-13 | 苏州宜联生物医药有限公司 | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 |
| EP4527415A1 (en) | 2022-05-18 | 2025-03-26 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof |
| CN116063521B (zh) * | 2022-10-31 | 2024-05-14 | 北京奇迈永华生物科技有限公司 | 靶向bcma的抗体及其所构成的嵌合抗原受体 |
| WO2024106939A1 (ko) * | 2022-11-15 | 2024-05-23 | 주식회사 셀랩메드 | B7-h3에 특이적으로 결합하는 항체 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| WO2024238966A1 (en) * | 2023-05-18 | 2024-11-21 | RNAimmune, Inc. | Anti-pd-l1 antibodies and uses thereof |
| AU2024295016A1 (en) * | 2023-07-20 | 2026-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors |
| TW202528354A (zh) * | 2024-01-03 | 2025-07-16 | 中國商北京泰德製藥股份有限公司 | B7-h3結合蛋白及其用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US7390885B2 (en) * | 2001-11-26 | 2008-06-24 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| ATE548389T1 (de) * | 2004-08-03 | 2012-03-15 | Innate Pharma | Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor |
| JP2008527001A (ja) | 2005-01-13 | 2008-07-24 | ザ ジョンズ ホプキンス ユニバーシティー | 前立腺幹細胞抗原ワクチンおよびその使用 |
| WO2006117910A1 (ja) * | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| GB0908816D0 (en) | 2009-05-21 | 2009-07-01 | Royal Holloway University Of L | Method |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| SMT201800269T1 (it) | 2011-04-25 | 2018-07-17 | Daiichi Sankyo Co Ltd | Anticorpo anti-b7-h3 |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| WO2014160627A1 (en) | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
| CA2921639A1 (en) | 2013-09-05 | 2015-03-12 | Aduro Biotech Holdings, Europe B.V. | Cd70-binding peptides and method, process and use relating thereto |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| EP3149040A1 (en) | 2014-05-29 | 2017-04-05 | Spring Bioscience Corporation | Anti-b7-h3 antibodies and diagnostic uses thereof |
| WO2017044699A1 (en) | 2015-09-10 | 2017-03-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 chimeric antigen receptors |
| CN108136010A (zh) * | 2015-10-08 | 2018-06-08 | 宏观基因有限公司 | 用于治疗癌症的联合疗法 |
| TWI781098B (zh) * | 2016-04-15 | 2022-10-21 | 美商宏觀基因股份有限公司 | 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法 |
| EP3448874A4 (en) * | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3458479B1 (en) * | 2016-06-08 | 2020-11-04 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| WO2018013611A1 (en) | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
| BR112019001570A2 (pt) | 2016-07-28 | 2019-07-09 | Novartis Ag | terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1 |
| EP3604337A4 (en) | 2017-03-31 | 2021-03-10 | Jiangsu Hengrui Medicine Co. Ltd. | B7-H3 ANTIBODIES, ANTIGIBODY FRAGMENT THEREOF, AND MEDICAL USES THEREOF |
-
2019
- 2019-11-15 US US17/294,560 patent/US12252538B2/en active Active
- 2019-11-15 WO PCT/US2019/061887 patent/WO2020102779A1/en not_active Ceased
- 2019-11-15 CN CN201980089456.0A patent/CN113330034A/zh active Pending
- 2019-11-15 JP JP2021526660A patent/JP7682789B2/ja active Active
- 2019-11-15 EP EP19885550.4A patent/EP3880712A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7682789B2 (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| Safarzadeh Kozani et al. | Nanobody-based CAR-T cells for cancer immunotherapy | |
| JPWO2020102779A5 (https=) | ||
| JP7438958B2 (ja) | 新規な抗体分子、その調製方法及びその使用 | |
| JP2024125370A (ja) | クローディン１８．２結合部分およびその利用 | |
| JP2017186337A5 (https=) | ||
| JP2018027952A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2021502104A5 (https=) | ||
| ES2528167T3 (es) | Tratamiento de tumores usando anticuerpo anti-L1, específico. | |
| JP2015502138A5 (https=) | ||
| JP2013502913A5 (https=) | ||
| US20220089752A1 (en) | Compositions and methods for modulating cellular internalization | |
| JP2019509055A5 (https=) | ||
| KR20190120792A (ko) | 폐암의 치료를 위한 항-pd-1 항체 | |
| ME02369B (me) | Antitela za terapiju kancera koji eksprimira klaudin 6 | |
| JP2018507188A5 (https=) | ||
| CN110603265A (zh) | 用于用抗间皮素免疫治疗癌症的组合物和方法 | |
| JP2018524300A5 (ja) | 組成物、抗体および結合性フラグメント | |
| RU2016101109A (ru) | Медицинское применение агонистов cd38 | |
| JP2022065159A5 (https=) | ||
| WO2022262678A1 (zh) | 一种多特异性抗原结合蛋白及其应用 | |
| JP2022526841A5 (https=) | ||
| JP2023015171A (ja) | 癌の組合せ治療 | |
| JP2022550364A (ja) | 新規抗ｐｄ－ｌ１／抗ｌａｇ－３二重特異性抗体およびその使用 |